Kanker-actueel Velcade - Bortezomib: what is this means and what cancers it is used: an overview of recent developments

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

VELCADE ™ (bortezomib) is from May 2004 officially registered drug against multiple myeloma - Multiple Myeloma in Europe including the Netherlands. Article updated December 5, 2010

VELCADE ™ (bortezomib) also by FDA, dated March 25, 2005 - officially registered drug against multiple myeloma - Multiple Myeloma

VELCADE ™ (bortezomib) from April 2005 officially registered drug as second-line treatment for multiple myeloma - Multiple Myeloma in Europe including the Netherlands.

Two large randomized studies to prove VELCADE (R) (Bortezomib) highly significant positive impact as first line treatment for multiple myeloma - Multiple Myeloma. and more open perspective for Kahler curative stem cell transplant patients. In the Netherlands large randomized phase III study of Velcade as a first line and in preparation for stem cell and open Kahler for 800 patients.

Velcade - Bortezomib study results in prostate cancer patients with recurrence of advanced prostate cancer. Update December 5, 2010

Velcade - Bortezomib also shows significant value in forms of non-Hodgkin's Phase II study says

Velcade - Bortezomib shows promising therapeutic value in patients with relapsed mantle-cell lymphoma and also encouraging results in patients with recurrent B-cell lymphomas other, said phase II study in 60 patients

Velcade - MLN341 gets official status of registered drug in Kahler - Multiple Myeloma after the USA now in Europe and provides various types of cancer remission spectacular effects said several studies with both animals and humans.

Velcade - Bortezomib, an overview of recent developments. Update December 5, 2010

VELCADE ™ (bortezomib) information